United Parcel Service is investing $48 million to upgrade 27 temperature-controlled facilities across its domestic and international operations as demand for healthcare logistics continues to grow, according to a June 22 CNBC report.
The facilities, located across the Americas, Europe and Asia, are designed to handle products that require strict temperature controls during transit, including biologic medicines and pharmaceuticals.
UPS said the investment will strengthen its cold-chain network and improve speed and chain-of-custody tracking for temperature-sensitive shipments. The market for temperature-sensitive biologics is projected to grow at an 8.3% compound annual growth rate through 2033 and reach a value of about $39.1 billion, according to the report.
The investment comes as demand for GLP-1 medications continues to rise. A November KFF poll found that 1 in 8 Americans are taking GLP-1 drugs, which require refrigeration and temperature control during transport. In 2025, GLP-1s accounted for 14% of U.S. drug spending, costing $131.9 billion of the $915.2 billion spent on all prescriptions. Medicare will also begin covering weight loss GLP-1s in July, a move expected to broaden access to the drugs.
